The FDA's Experience with Emerging Genomics Technologies-Past, Present, and Future
about
Reproducibility in biomarker research and clinical development: a global challenge.Talking the talk, but not walking the walk: RT-qPCR as a paradigm for the lack of reproducibility in molecular research.Population-based dose-response analysis of liver transcriptional response to trichloroethylene in mouse.
P2860
The FDA's Experience with Emerging Genomics Technologies-Past, Present, and Future
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 26 April 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The FDA's Experience with Emerging Genomics Technologies-Past, Present, and Future
@en
The FDA's Experience with Emerging Genomics Technologies-Past, Present, and Future.
@nl
type
label
The FDA's Experience with Emerging Genomics Technologies-Past, Present, and Future
@en
The FDA's Experience with Emerging Genomics Technologies-Past, Present, and Future.
@nl
prefLabel
The FDA's Experience with Emerging Genomics Technologies-Past, Present, and Future
@en
The FDA's Experience with Emerging Genomics Technologies-Past, Present, and Future.
@nl
P2093
P2860
P1433
P1476
The FDA's Experience with Emerging Genomics Technologies-Past, Present, and Future
@en
P2093
Binsheng Gong
Shraddha Thakkar
P2860
P2888
P304
P356
10.1208/S12248-016-9917-Y
P407
P50
P577
2016-04-26T00:00:00Z
2016-07-01T00:00:00Z
P6179
1005034548